New vaccine shows promise against Traveler's diarrhea in early trial
NCT ID NCT06692907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental vaccine (CssBA+dmLT) to see if it can prevent moderate-to-severe diarrhea caused by ETEC bacteria, a common cause of traveler's diarrhea. About 72 healthy adults received either the vaccine or a placebo, then were exposed to the bacteria in a controlled setting. The goal was to measure how well the vaccine protects against diarrhea and to check for any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCHERICHIA INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229-3039, United States
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States